Saluda Medical
PrivateLast Round
IPO Announced
Dec 5, 2025
Est. Valuation
$433.04M
Total Funding Raised
$284.1M
Momentum Score
25 /100
Company Overview
Saluda Medical is a commercial-stage global medical device company that develops and commercializes neuromodulation therapies for chronic neurological conditions. Its core technology is a closed-loop, dose-control platform designed to sense and measure the spinal cord's response to stimulation (via Evoked Compound Action Potentials or ECAPs) and automatically adjust therapy in real-time. The company's first product, the Evoke® System, is the first and only FDA-approved spinal cord stimulation (SCS) system with this capability, indicated for treating chronic intractable pain. By providing a more precise and personalized treatment, the system aims to deliver more consistent and effective outcomes compared to traditional open-loop SCS systems. The company has received significant venture and private equity funding to support the commercialization of its Evoke system and to advance its technology platform.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Precision Medicine, Sensors, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Saluda Medical Comps
Public and private peers based on sector, stage, and business model.
Saluda Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO Announced | Dec 5, 2025 | ||||
| VC Round | Nov 12, 2025 | ||||
| VC Round | Jan 10, 2025 | ||||
| Series F | Apr 13, 2023 | ||||
| VC Round | Mar 2, 2022 | ||||
Series E | Jun 28, 2019 |
Key People
Founding team and executive leadership
Saluda Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TPG Life Sciences Innovations | IPO |
| Redmile Group | IPO, Series F, VC Round, Series E |
| BioScience Managers | Series F |
| Heartland Healthcare Capital | VC Round |
| Action Potential Venture Capital | VC Round, Series F, Series D |
| Fidelity Management & Research Company | VC Round, IPO, Series F |
| Bell Potter Securities | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 5, 2025
$150M raised in IPO round.
- Jul 18, 2025
EVA, advanced sensing technology for neuromodulation, is now commercially available in the United States.
Saluda Medical Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Saluda Medical's valuation, stock price, and market status.
